Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Spherix Global Insights
< Previous
1
2
3
4
5
Next >
Spherix Global Insights Finds Benlysta Exposure Expanding and Rheumatologists Increasingly Turning to Lupkynis in Lupus Nephritis
March 06, 2026
From
Spherix Global Insights
Via
GlobeNewswire
Paroxysmal Nocturnal Hemoglobinuria Market Enters Transition Phase as Second-Line Opportunities Expand Amid Ongoing Barriers to Adoption of Newer Agents, According to Spherix Global Insights
March 05, 2026
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Expands Advisory Capabilities with Launch of a New Market Access Suite of Services
March 03, 2026
From
Spherix Global Insights
Via
GlobeNewswire
One in Three Rheumatologists View BMS’ Sotyktu as a Substantial Advance in Psoriatic Arthritis Ahead of March 6 FDA Decision, According to Spherix Global Insights Data
February 27, 2026
From
Spherix Global Insights
Via
GlobeNewswire
Otsuka Pharmaceutical’s VOYXACT Gains Early Traction in IgAN, with 21% of Nephrologists Reporting Prescribing Within Two Months of Approval
February 24, 2026
From
Spherix Global Insights
Via
GlobeNewswire
Novo Nordisk’s Wegovy® Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral GLP-1s in Obesity
February 20, 2026
From
Spherix Global Insights
Via
GlobeNewswire
Gazyva Establishes Early Clinical Credibility in Lupus Nephritis Three Months Post-Approval, According to Spherix Global Insights
February 17, 2026
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Reveals Persistent High Disease Burden and Heavy Reliance on Pain Management in U.S. Sickle Cell Disease Despite Awareness of Disease-Modifying Therapies
February 05, 2026
From
Spherix Global Insights
Via
GlobeNewswire
Rheumatologists Sharpen Differentiation Across the SLE Pipeline as Late-Stage Assets Crystallize into More Defined Clinical Roles, According to Spherix Global Insights
January 20, 2026
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
January 14, 2026
From
Spherix Global Insights
Via
GlobeNewswire
New Spherix Patient Research Shows Nearly Half of Atopic Dermatitis Patients Report Major Quality-of-Life Impact Despite Expanding Treatment Options
January 08, 2026
From
Spherix Global Insights
Via
GlobeNewswire
UCB’s Bimzelx Continues to Shift Biologic Treatment Patterns in Hidradenitis Suppurativa as Demand for Innovation Grows, According to Spherix Global Insights
December 17, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Approval of Roche/Genentech’s Gazyvaro Set to Reshape the EU5 Lupus Nephritis Treatment Landscape, According to Spherix Global Insights
December 11, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Amid Escalating Market Investment, Physicians Forecast Rapid Uptake of Oral Semaglutide Upon Approval in Obesity, According to Spherix Global Insights
December 09, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Conflicting Guidance and Rapid Innovation Leave Physicians Seeking Clarity in Relapsed/Refractory Multiple Myeloma
December 02, 2025
From
Spherix Global Insights
Via
GlobeNewswire
First Look at Roche/Genentech’s Gazyva Shows Strong Early Enthusiasm in Lupus Nephritis Launch, According to Spherix Global Insights
November 19, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Reports Rapidly Evolving U.S. PNH Market as Ultomiris Prescriptions Reach Parity with Iron Supplements
November 19, 2025
From
Spherix Global Insights
Via
GlobeNewswire
UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondyloarthritis Growth
November 13, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Reveals Unmet Need Driving Interest in Emerging Therapies for Thyroid Eye Disease
November 12, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Novel Pipeline Activity Signals Hope in Systemic Sclerosis, as Rheumatologists Anticipate First Real Therapeutic Advances in Years
November 06, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations in ALS, Parkinson’s, and Neuroimmune Disorders
November 03, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Launches Market Dynamix™: PD-1 Inhibition in Solid Tumors, Delivering a Comprehensive Assessment of Biosimilar and Subcutaneous PD-1 Market Dynamics Across Key Oncology Indications
October 31, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Targeted Biologics Expand in Early-Line gMG Treatment as New Entrants Prepare to Challenge Established Leaders
October 29, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Step Therapy Shifts and Pipeline Momentum Reshape the Membranous Nephropathy Treatment Landscape, according to Spherix Global Insights
October 28, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Evolving Treatment Landscape for Chronic Spontaneous Urticaria Highlights Significant Unmet Needs and Expanding Opportunities for Therapeutic Innovation
October 24, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Hemophilia Specialists Raise the Bar: Quality of Life and Innovation Drive Market Reordering
October 22, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Sjögren’s Disease Remains an Underdiagnosed and Underguided Condition, Creating an Opening for Manufacturers to Shape the Future of Care, According to Spherix Global Insights
October 16, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Expands Hematology Franchise to Include Oncology, Enhancing Advisory Services and Delivering Deeper Physician and Market Insights
October 15, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Identifies Emerging Trends in Market Access Across More Than Twenty Key Therapeutic Areas
October 14, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Priovant’s Brepocitinib Poised to Address Steroid-Sparing Gap in Dermatomyositis as Rheumatologists Anticipate 2026 Launch
October 10, 2025
From
Spherix Global Insights
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.